ArticleAntimicrobial agents and chemotherapy2026
Phosphate sensitivity of KPC-2: a hidden variable in β-lactamase kinetics.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The catalytic activity of β-lactamases, particularly class A enzymes like KPC-2, is central to β-lactam antibiotic resistance. While phosphate buffers are widely used in enzymatic assays due to their physiological relevance, their potential to interfere with enzyme function remains underappreciated. Here, we demonstrate that phosphate acts as a competitive inhibitor of KPC-2 β-lactamase, significantly reducing catalytic efficiency in a concentration-dependent manner. This inhibition is mediated through interactions with threonine 237, as substitution with glycine (T237G) abolishes the inhibitory effect. In contrast, CTX-M-14 and TEM-1, which possess serine and alanine at the same position, respectively, exhibit minimal phosphate sensitivity, underscoring enzyme-specific buffer effects. Structural and kinetic analyses indicate that phosphate binding at the active site primarily impairs substrate affinity and, in some cases, also reduces catalytic turnover. These findings highlight the potential impact of buffer selection in β-lactamase assays and suggest that phosphate-mediated inhibition may lead to underestimation of enzyme activity and inhibitor potency, particularly in studies involving KPC-2. Standardizing assay conditions is essential for accurate evaluation of β-lactamase function and resistance mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.